Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Current Assets (2016 - 2025)

Historic Current Assets for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $147.3 million.

  • Cartesian Therapeutics' Current Assets fell 3573.25% to $147.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.3 million, marking a year-over-year decrease of 3573.25%. This contributed to the annual value of $216.6 million for FY2024, which is 13876.16% up from last year.
  • Per Cartesian Therapeutics' latest filing, its Current Assets stood at $147.3 million for Q3 2025, which was down 3573.25% from $163.4 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Current Assets registered a high of $229.1 million during Q3 2024, and its lowest value of $89.9 million during Q3 2023.
  • In the last 5 years, Cartesian Therapeutics' Current Assets had a median value of $148.1 million in 2022 and averaged $150.3 million.
  • In the last 5 years, Cartesian Therapeutics' Current Assets skyrocketed by 17322.94% in 2021 and then crashed by 4371.83% in 2023.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Current Assets stood at $144.4 million in 2021, then rose by 2.56% to $148.1 million in 2022, then plummeted by 38.75% to $90.7 million in 2023, then surged by 138.76% to $216.6 million in 2024, then plummeted by 32.02% to $147.3 million in 2025.
  • Its last three reported values are $147.3 million in Q3 2025, $163.4 million for Q2 2025, and $185.1 million during Q1 2025.